-+ 0.00%
-+ 0.00%
-+ 0.00%

TUKYSA ADDED TO FIRST-LINE MAINTENANCE THERAPY EXTENDS MEDIAN PROGRESSION-FREE SURVIVAL BY OVER 8 MONTHS IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER

Reuters·12/10/2025 13:15:05

Please log in to view news